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INTRODUCTION 
 
Skeletal muscle wasting may occur in several physio-
pathological conditions and represents one of  
the main overlapping features between the 
physiological age-related sarcopenia and cachexia, 
which often associates with an underlying  
disease, such as cancer, especially in terminally ill 
patients.  
In both cases, the occurrence of chronic systemic 
inflammation may directly contribute to the loss of 
skeletal muscle mass and functionality [1–5]. 
 
Another feature often associated with both muscle 
wasting-inducing conditions is an important reduction 
of vitamin D3, seen as decreased 25(OH)D3 (25-
hydroxycholecalciferol, hereafter 25VD) circulating 
levels [6, 7]. 
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We previously determined that different vitamin D metabolites can have opposite effects on C2C12 myotubes, 
depending on the sites of hydroxylation or doses. Specifically, 25(OH)D3 (25VD) has an anti-atrophic activity, 
1,25(OH)2D3 induces atrophy, and 24,25(OH)2D3 is anti-atrophic at low concentrations and atrophic at high 
concentrations. This study aimed to clarify whether cholecalciferol (VD3) too, the non-hydroxylated upstream 
metabolite, has a direct effect on muscle cells. 
Assessing the effects of VD3 treatment on mouse C2C12 skeletal muscle myotubes undergoing atrophy 
induced by interleukin 6 (IL6), we demonstrated that VD3 has a protective action, preserving C2C12 
myotubes size, likely through promoting the differentiation and fusion of residual myoblasts and by 
modulating the IL6-induced autophagic flux. The lack, in C2C12 myotubes, of the hydroxylase transforming 
VD3 in the anti-atrophic 25VD metabolite suggests that VD3 may have a direct biological activity on the 
skeletal muscle. Furthermore, we found that the protective action of VD3 depended on VDR, implying that 
VD3 too might bind to and activate VDR. However, despite the formation of VDR-RXR heterodimers, VD3 
effects do not depend on RXR activity. 
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In humans, vitamin D3 synthesis begins with skin 
exposure to ultraviolet B radiation and the consequent 
photochemical conversion of the precursor, 7-
dehydrocholesterol (pro-vitamin D3), in pre-vitamin D3. 
Through thermal isomerization, pre-vitamin D3 is 
converted to vitamin D3 (cholecalciferol, hereafter 
VD3), which is hydroxylated in the liver by the 25-
hydroxylases (25-OHases encoded by CYP27A1 and 
CYP2R1 genes); the resultant 25VD is further 
converted in 1,25(OH)2D3 (1,25-dihydroxy vitamin D3 
or calcitriol, hereafter 1,25VD) in the kidney by  
1α-hydroxylase (1α-OHase, encoded by the CYP27B1 
gene). Lastly, the 24-hydroxylase encoded by the gene 
CYP24A1 catalyzes the conversion of both 25VD and 
1,25VD into 24-hydroxylated products targeted for 
inactivation and excretion.  
 
1,25VD exerts its biological activities through the binding 
to vitamin D receptor (VDR), inducing the 
heterodimerization of VDR with the retinoic acid receptor 
RXR, the recruitment of various coregulators, and the 
binding of this complex to specific regions on DNA. 
Though the bone is the best-known target of vitamin D, 
VDR is almost ubiquitously expressed through the cells 
and tissues of the body, suggesting that vitamin D has 
wide pleiotropic activities. Likewise, the widespread 
extra-renal expression of the CYP27B1 hydroxylase 
suggests that 25VD could be locally converted to 1,25VD, 
thus providing a mechanism explaining the ever-growing 
observations of 25VD-elicited biological activities [8, 9]. 
Nevertheless, we have demonstrated that, in C2C12 
myotubes, 25VD has a biological anti-atrophic activity 
that does not depend on its intracellular conversion to 
1,25VD. Unexpectedly, in this in vitro model of skeletal 
muscle, 25VD and 1,25VD have antithetical effects, likely 
via differential modulation of 24-hydroxylase [10]. 
Furthermore, we showed that, on C2C12 myotubes, 
24,25(OH)2D3 (24,25VD) itself could have divergent 
effects, either atrophic or hypertrophic, depending on its 
concentration. These observations are in accordance with 
and strengthen the idea that all vitamin D3 metabolites, 
and not only 1,25VD, might be biologically active [11, 
12]. Proceeding with this view, here we explored the 
hypothesis that VD3 as well could have a direct biological 




VD3 treatment protects C2C12 myotubes and 
primary myofibers from IL6 induced atrophy 
 
To assess whether VD3 could have protective activity in 
the skeletal muscle, we mimicked in vitro the condition 
of inflammation-prompted muscle wasting by treating 
murine C2C12-derived myotubes with the pro-atrophic 
cytokine interleukin-6 (IL6) [10]. C2C12 myotubes 
incubated for 24 h with 20 ng/ml IL6 underwent 
consistent atrophy, appraised as a reduction of 20% in 
myotube thickness (Figure 1A). Co-treatment with VD3 
prevented the reduction of myotube diameter in a dose-
dependent manner, starting from 1 nM concentrations. At 
concentrations of 10 and 100 nM, VD3 completely 
blocked the atrophic effect of IL6, while VD3 alone had 
no evident effects on C2C12 myotube size (Figure 1A). 
A similar result was obtained treating freshly isolated 
myofibers with IL6 in the presence or absence of VD3 
(Figure 1B), supporting the choice of C2C12 myotubes 
as a suitable model to study skeletal muscle homeostasis.  
 
To investigate if the changes in myotube diameters upon 
IL6 and VD3 treatments could derive from differentiative 
effects on the residual undifferentiated myoblasts in 
culture [13], we calculated the variation in differentiation 
and fusion indexes during the experimental period both in 
control (untreated cultures) and treated conditions. 
Although there was no additional differentiation of 
untreated myoblasts cultured in differentiation medium 
within the experimental period, VD3 promoted a further 
20% differentiation that influenced, although not to a 
statistically significant extent, the differentiation of the 
combined treatment of IL6 and VD3 (Figure 1C). 
However, the fusion of residual myoblasts was 
significantly promoted by VD3 treatment, both alone and 
in combination with IL6 (Figure 1D). Conversely, IL6 
treatment did not affect differentiation or fusion of 
residual myoblasts. 
 
VD3 does not promote protein synthesis but 
activates STAT3 
 
Skeletal muscle homeostasis depends on the balance 
between anabolic and catabolic processes; however, the 
lack of any effect of VD3 treatment on myotube and 
myofiber diameters (Figure 1A, 1B) suggested that VD3 
could not stimulate protein synthesis. To verify this 
hypothesis, we assessed if VD3 could stimulate the de 
novo synthesis of proteins through a SUnSET assay. 
Although we observed a mild increase in puromycin 
incorporation (Figure 2A), this was not significant. 
Coherently, VD3 treatment did not induce the activation 
of the Akt/mTOR protein network associated with 
protein synthesis (Figure 2B). 
 
As IL6 promotes muscle wasting mainly through STAT3 
activation, and STAT3 inhibition prevents IL6-induced 
atrophy [14], we investigated if VD3 treatment could curb 
IL6-elicited STAT3 signaling. As expected, IL6 induced 
rapid phosphorylation of STAT3Tyr705 within the first 30 
minutes of treatment. However, unexpectedly, VD3 not 
only did not inhibit IL6-induced STAT3 activation but 
induced itself the phosphorylation of STAT3Tyr705 (Figure 
2C). Even more surprisingly, the co-treatment of VD3 and 
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IL6 induced significant phosphorylation of STAT3Tyr705 at 
24 h post-treatment that was not induced by the single 
treatments (Figure 2D). 
 
VD3 modulates the autophagic flux in IL6-treated 
C2C12 myotubes 
 
Autophagy is another mechanism that can regulate 
muscle homeostasis by regulating protein and organelle 
turnover [15, 16]. Therefore, we investigated whether 
IL6, VD3, and their combination could affect autophagy 
by measuring the accumulation of the lipidated 
autophagosomal marker LC3II in C2C12 myotubes 
lysates in the presence or absence of chloroquine, a 
blocker of the autophagic flux. We observed that the 
autophagic flux was slightly reduced when VD3 and IL6 
were co-administered (Figure 3A). Thus, we assessed the 
accumulation of LC3 puncta in myotubes by 
immunofluorescence and observed that the modest 
increase of IL6-induced autophagic flux was significantly 
reduced by VD3 co-treatment (Figure 3B), thus 
confirming the trend perceived in western blot.  
 
VD3 anti-atrophic activity does not depend on its 
intracellular conversion to 25VD  
 
The complexity of vitamin D biological activity is further 
complicated by the ability of distinct vitamin D 
metabolites to modulate the expression of the 
hydroxylases involved in vitamin D metabolism and of 
VDR [17]. To explore if the hitherto observed effects of 
VD3 on C2C12 myotubes could depend on its 
transformation in other metabolites with already proven 
biological activity, we assessed the expression of the main 
players of vitamin D metabolism upon VD3 treatment. In 
particular, as we have previously demonstrated that 25VD 
has a powerful anti-atrophic activity in C2C12 myotubes 
treated with pro-cachectic cytokines, including IL6 [10], 
we explored the hypothesis that the observed anti-atrophic 
effect of VD3 could be due to its intracellular conversion 
to 25VD in C2C12 myotubes. In vivo, VD3 is 
hydroxylated in the liver by Cyp2r1 and Cyp27a1 25-
hydroxylases to yield 25VD. Using murine liver as a 
positive control, we found that in C2C12 myotubes 
Cyp27a1 showed a low but measurable expression 
(Figure 4A), while Cyp2r1 (in mouse, the main 25-
hydroxylase [18, 19]) was undetectable, both basally and 
upon stimulation with VD3 or IL6 (data not shown), 
suggesting a direct biological action of VD3 on C2C12 
myotubes. We verified this hypothesis by quantifying, 
with a specific ELISA, the 25VD produced intracellularly 
upon 24 h of VD3 treatment. We demonstrated that 
C2C12 myotubes, differently from liver-derived cells, 
were unable to metabolize VD3 into 25VD (Figure 4B), 
ruling out that the observed anti-atrophic effects derived 
from the intracellular conversion of VD3 in 25VD. 
In addition, we found that, similarly to 25VD and 
1,25VD [20], VD3 did not affect the expression of 
Cyp27b1, coding for the 1α-hydroxylase (Figure 3C). 
However, differently from 25VD and 1,25VD 
metabolites [10, 20], VD3 did not modulate the 
expression of the 24-hydroxylase gene Cyp24a1 (Figure 
4D), nor that of Vdr (Figure 4E). Also, VD3 did not 
affect the expression of Pdia3, the gene encoding for the 
1,25D3-MARRS (Membrane Associated, Rapid 
Response Steroid binding), an alternative vitamin D 
receptor regarded as the one mediating the membrane-
initiated signaling of 1,25VD (Figure 4F).  
 
VD3 anti-atrophic activity is VDR-dependent but 
RXR-independent  
 
Although VD3 does not modulate the expression of 
Vdr (Figure 4E), the silencing of Vdr completely 
abrogated the protective activity of VD3 against IL6-
induced atrophy (Figure 5A), indicating that VDR 
mediates VD3 anti-atrophic activity in C2C12 
myotubes. The atrophic activity of 1,25VD [10] was 
abolished by VDR silencing, as expected. Through a 
proximity ligation assay (PLA), we observed that, in 
C2C12 myotubes, VD3, similarly to 1,25VD, induced 
the formation of VDR-RXR complexes, although with 
different kinetics (Figure 5B, 5C). Notably, the 
formation of the VDR-RXR complexes was evenly 
distributed in both cytoplasmic and nuclear 
compartments, without a remarkable nuclear 
translocation, i.e., an increase in nuclear/cytoplasmic 
ratio (upper panels of Figure 5C). Conversely, in the 
residual myoblasts (visible in the representative 
pictures as nuclei belonging to myosin heavy chain 
(MyHC)-negative cells), both VD3 and 1,25VD 
promoted both the formation of VDR-RXR complexes 
over time and their nuclear translocation (lower 
panels of Figure 5C).  
 
However, despite the formation of VDR-RXR 
complexes, differently from 1,25VD, RXR activity was 
not required for the effects of VD3 in C2C12 myotubes, 
as the inhibition of RXR with 2.5 μM PA 452 abolished 
only 1,25VD but not VD3 effects (Figure 5D). We 
finally assessed the involvement of the alternative 
1,25D3-MARRS receptor in VD3 anti-atrophic action. 
The silencing of Pdia3 did not affect the activity of 
VD3 (Figure 5E), indicating that 1,25D3-MARRS does 
not mediate VD3 anti-atrophic effect.  
 
VD3 does not protect C2C12 myotubes from 
dexamethasone-induced atrophy 
 
To investigate if VD3 could have a broad anti-atrophic 
activity, we assessed its effect by co-treating C2C12 
myotubes undergoing atrophy upon treatment with 
 
www.aging-us.com 4898 AGING 
dexamethasone, a synthetic glucocorticoid that induces 
muscle protein degradation via the activation of the 
ubiquitin-proteasome system [21]. Myotubes were 
treated with 5 μM dexamethasone for 24 h in the 
presence or absence of 100 nM VD3. Treatment with 
dexamethasone reduced myotube diameters by 10% and 
induced the muscle-specific ubiquitin ligase Atrogin-1 




Figure 1. VD3 protects C2C12 myotubes and isolated myofibers from IL6-induced atrophy. (A) Myotubes were treated in 
serum-free medium with 100 nM VD3, 20 ng/ml IL6 alone or in combination with decreasing concentrations (100 – 0.01 nM) of VD3 
for 24 h. At the end of the indicated treatments, myotube diameters were measured either in phase -contrast images or after 
immunofluorescence (IF) with anti-MyHC antibody and DAPI counterstaining. Representative images of myotubes in both phase-
contrast and IF are shown at the bottom of the panel. Scale bar, 100 μm (B) Single myofibers were isolated from C57BL/6 mice and 
treated with 20 ng/ml IL6 alone or in combination with 100nM VD3. Myofiber diameters were acquired from phase-contrast images 
(representative images at the bottom of the panel). (C) Differentiation and (D) fusion indexes after 24 h of VD3 and IL6 treatments 
compared to the time of treatment administration (0 h; C2C12 differentiated for at least 4 days in DM). Data are presented as the 
mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001. 
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Figure 2. VD3 does not stimulate protein synthesis but activates STAT3. (A) Protein synthesis upon 24 h of treatment with 20 ng/ml 
IL6 in the presence or absence of 100nM VD3 was evaluated by SUnSET assay. Incorporation of puromycin into newly synthesized proteins 
was visualized by Western blotting and normalized on total proteins detected by Ponceau staining (representative images on the left of the 
panel). Densitometry of three experiments is shown on the right part of the panel. (B) Relative phosphorylation of proteins of Akt pathway 
after 30 min treatment with 100 nM VD3 through protein array analysis. (C) Representative western blot (top) and densitometry (bottom) of 
phosphorylated STAT3Y705 levels in C2C12 myotubes treated with 100 nM VD3, 20ng/mL IL6, or their combination for the indicated times. (D) 
Western blot (left) and densitometry (right) of phosphorylated STAT3Y705 levels in C2C12 myotubes treated with VD3, IL6, or their 
combination for 24 h. Data are presented as the mean ± SEM of three independent experiments except for (D), in which data are presented 
as the mean ± SD of the independent experiments indicated on the blot. **P<0.01. 
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Figure 3. VD3 modulates the autophagic flux in IL6-treated C2C12 myotubes. C2C12 myotubes in DM were treated for 24 h with 
100 nM VD3, 20ng/mL IL6, or their combination in the presence and absence of 10 µM of chloroquine (CLQ). The autophagosome marker LC3 
was detected by western blotting (A) or immunofluorescence (B). Autophagic flux was assessed by quantifying the ratio of LC3 signal in  
the presence vs. absence of CLQ. For each panel, representative images are on the top and quantification on the bottom. Scale bar, 50 μm. 
**P < 0.01. 
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atrophy (Figure 6A, 6B), indicating that VD3 ability to 




The impact of vitamin D on muscle morphology and 
functionality has been largely investigated, and vitamin D 
deficiency has been implicated in pathological conditions 
such as frailty and sarcopenia in the elders and cachexia 
in cancer patients [6, 22]. Even though vitamin D 
deficiency correlates with muscular impairment, the 
effectiveness of vitamin D supplementation depends on 
the context of use. In fact, a relevant number of 
epidemiological studies have suggested the potential role 
of vitamin D intake to maintain or improve muscle 
strength and function in older people [23]. On the other 
hand, the efficacy of vitamin D supplementation in 
cancer cachexia associated with low levels of plasmatic 
vitamin D remains non-conclusive, both in human and in 
rodent experimental models [22, 24, 25]. 
 
In our previous attempt to better understand these 
different biological responses in the skeletal muscle to 
vitamin D supplementation, we realized that, in vitro, 
different vitamin D metabolites have distinctive 
activities. In particular, we conjectured that a different 
extent of 24-hydroxylase modulation by 25VD and 
1,25VD results in divergent effects on C2C12 
myotubes, being 25VD protective against cytokine-
induced atrophy and 1,25VD atrophic per se. 
Furthermore, 24,25VD itself can either protect or 




Figure 4. VD3 did not alter the expression of hydroxylases and receptors involved in vitamin D metabolism and activity, and 
its anti-atrophic action does not depend on intracellular conversion to 25VD. (A) C2C12 myotubes were treated in serum-free 
medium with VD3 for 24 h, and mRNA levels of Cyp27a1 were assayed by real-time PCR, using liver tissue as a positive control and Gusb as 
the housekeeping gene. (B) HepG2 cells and C2C12 myotubes were treated in serum-free medium with VD3 for 24 h, and the content of 
25VD was quantified in cell lysates with a specific ELISA kit. (C–F) C2C12 myotubes were treated in serum-free medium as above, and mRNA 
levels of (C) Cyp27b1, (D) Cyp24a1, (E) Vdr, and (F) Pdia3 were assayed by real-time PCR, using Gusb as the housekeeping gene. Data are 
presented as the mean ± SEM of three independent experiments. ***P < 0.001. 
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Figure 5. VDR, but not RXR nor 1,25D3-MARRS (Pdia3), mediates VD3 anti-atrophic activity. (A) C2C12 myotubes were 
transfected with non-targeting or Vdr specific siRNAs. 24 h after silencing, C2C12 myotubes were treated with 20ng/mL IL6 in the absence or 
presence of 100 nM VD3 or with 100 nM 1,25VD, and myotube diameters were measured after further 24 h. (B) Representative images of 
the PLA-detected complexes of VDR and RXR (red) in C2C12 myotubes (green) treated for the indicated times with 100 nM VD3 or 100 nM 
1,25VD. Nuclei were stained with DAPI. The white arrows indicate the nuclei of bone fide residual undifferentiated myoblasts. (C) 
Quantification of the PLA dots in myotubes (top) or myoblasts (bottom), in nuclei (left), cytoplasm (middle), and their ratio (right). (D) 
Myotube diameters of C2C12 treated with 20ng/mL IL6, with or without 100 nM VD3, or with 100 nM 1,25VD, in the presence/absence of 2.5 
μM RXR inhibitor PA 452. (E) C2C12 myotubes were transfected with non-targeting or Pdia3 specific siRNAs, treated with 20ng/mL IL6 in the 
absence or presence of 100 nM VD3 and analyzed after further 24 h. Data are presented as the mean ± SEM. *P < 0.05; **P < 0.01; ***P < 
0.001 vs. non-treated controls (NT); $P < 0.05; $$P < 0.01 vs. VD3-treated cells. 
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Here, we showed that the un-hydroxylated VD3 could 
prevent IL6-induced atrophy in C2C12 myotubes and 
primary myofibers (Figure 1). Notably, the absence in 
these cells of Cyp2r1, the principal vitamin D 25-
hydroxylase in mice [18, 19], together with the inability 
of the other vitamin D 25-hydroxylase, Cyp27a1, to 
convert VD3 in 25VD in C2C12 myotubes (Figure 4B), 
rules out an intracellular conversion of VD3 in 25VD, 
whose anti-atrophic activity has already been 
demonstrated [10] and implies a direct activity of VD3 
in C2C12 myotubes. In addition, the loss of anti-
atrophic activity upon silencing of Vdr (Figure 4A) 
suggests that VDR could be bound by VD3 as well, 
besides 1,25VD and 25VD [26], although specific 
binding studies should be performed to confirm this 
hypothesis and determine the binding affinity. 
Furthermore, similarly to 1,25VD, VD3 induced the 
formation of VDR-RXR complexes, although with 
different kinetics (Figure 5B, 5C). Contrary to what one 
might expect, 1,25VD did not induce the nuclear 
translocation of VDR-RXR complexes in myotubes 
(Figure 5C). It should be noted, however, that the 
1,25VD-induced increase of the cellular amount of 
VDR [24] could partially disguise the monitoring of 
VDR-RXR translocation. The fact that RXR activity is 
dispensable for VD3 anti-atrophic action (Figure 5D) 
might suggest that the VD3-induced VDR-RXR 
interaction is less stable than that induced by 1,25VD. 
However, the hypothesis that VD3 binding to VDR 
does not stabilize the VDR-RXR complex needs further 
investigation. Intriguingly, VDR-RXR complexes 
showed a different pattern of cytosolic/nuclear 
localization in C2C12 myotubes vs. myoblasts  
(Figure 5B, 5C). Indeed, VDR-RXR complexes were 
evenly distributed in myotubes after VD3 or 1,25VD 
stimulation, while in myoblasts, both VD3 and 1,25VD 
clearly induced an increase of the VDR-RXR signal in 
the nuclei (Figure 5C). Although 1,25VD induces the 
increase of VDR in myoblasts as well, we hypothesize 
that the higher amount of VDR in myoblasts vs. 
myotubes [24] made it easier to visualize the nuclear 
translocation in this case. Altogether, these findings 
could account for the sometimes-discordant data in the 
literature about the effect of vitamin D metabolites in 
C2C12 or muscle-derived cells of different origin, as 
some studies were carried out on myoblasts [27–30], 
others during the differentiation from myoblasts to 
myotubes [29–31], and yet some others in differentiated 
myotubes [10, 24]. The presence of VDR-RXR 
complexes in nuclei upon VD3 treatment might imply 
that the anti-atrophic effect is genomic. Also, the lack of 
involvement of the alternative vitamin D receptor 
considered the one mediating the non-genomic activity 
of 1,25VD (Figure 5E) tends in that direction, although 
this notion should be further assessed with appropriate 
methods. 
 
Our data indicate that the anti-atrophic activity of VD3 
is not generic but depends on the stimulus inducing 
atrophy. Indeed, VD3 was unable to protect from 
dexamethasone-induced atrophy and to prevent the 
induction of the muscle-specific ubiquitin ligase 
Atrogin-1 (Figure 6). We could not detect an increase in 
Atrogin-1 expression in C2C12 myotubes upon IL6 
treatment (data not shown), and indeed the ability of 
IL6 to induce Atrogin-1 remains debated, with several 
works reporting contrasting findings [32]. Therefore, we 
can speculate that VD3 can protect from stimuli that do 
not involve, as the primary mechanism, the induction of 




Figure 6. VD3 does not protect myotubes against atrophy induced by dexamethasone. (A) Myotube diameters were measured 
after 24 h treatment with 5 µM dexamethasone (DEXA) alone or in combination with 100 nM VD3. (B) Expression of Atrogin-1 (Fbxo32) was 
assessed by real-time RT-PCR. Data are presented as the mean ± SEM. ** P <0.01. 
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activation of the proteasome system. Another reason for 
the lack of protection against dexamethasone-induced 
atrophy might lie in the heterodimerization of the 
glucocorticoid receptor (GR) with RXR, the main 
partner for VDR heterodimerization upon ligand 
binding. GR-RXR dimerization occurs in the case of 
dexamethasone-induced death of murine T-cells and 
thymocytes [33]. In the light of the involvement of 
VDR in the anti-atrophic activity of VD3 (Figure 5A), it 
is possible to speculate that dexamethasone signaling 
could induce the dimerization of GR with RXR, thus 
preventing the formation of VDR-RXR complex and 
the anti-atrophic activity of VD3. However, RXR 
activity is not required for VD3 anti-atrophic activity 
(Figure 5D); therefore, it is possible that the strong GR 
activation induced by dexamethasone could trap 
coregulators like steroid receptor coactivator-1 (SRC-1), 
modifying the mutual binding to glucocorticoid-  
and vitamin D-responsive elements (GREs and VDREs, 
respectively) on DNA and, consequently, the 
activation/inhibition of specific genes [34–36]. 
 
On the other hand, IL6-induced muscle atrophy mainly 
depends on the activation of STAT3, as its inhibition 
prevents muscle wasting [14]. Contrary to what one 
could expect, VD3, instead of inhibiting STAT3 
activation, phosphorylated it per se (Figure 2C). 
However, STAT3 activation in skeletal muscle has 
pleiotropic functions and apparently contradictory 
effects. In particular, STAT3 has a pivotal role in 
satellite cell myogenic progression in vitro and in vivo 
[37, 38]. Notably, treatment of myoblasts with sub-
atrophic doses of IL6 induced a different timing of 
JAK2/STAT3 signaling pathway activation depending 
on the concentrations used that, eventually, promoted 
either cell proliferation or differentiation [37]. We can 
speculate that a fine-tuning of STAT3 activation may 
lead C2C12 myotubes to different fates and that VD3-
induced activation of STAT3, either alone or in 
combination with IL6, tips the scales in favor of 
residual myoblasts differentiation instead of atrophy. A 
similar mechanism could also explain the effects on 
autophagy, as STAT3 activation may affect autophagy, 
with effects either anti- or pro-autophagic, depending on 
the cells and stimuli [39]. In skeletal muscle, STAT3 
activation inhibits starvation-induced macroautophagy, 
especially in glycolytic fibers [40, 41]. In C2C12 
myotubes, despite both IL6 and VD3 induced rapid 
STAT3 phosphorylation, only IL6 seemed to promote a 
modest autophagy, while co-treatment with VD3 clearly 
reduced it (Figure 3B). Notably, at 24 h post-treatment, 
STAT3 was phosphorylated only upon VD3 and IL6 co-
treatment (Figure 2D). If the effect of VD3 on 
autophagy induction depends on the late reactivation of 
STAT3 still needs to be investigated. Nevertheless, 
contrary to 25VD [10], the modulation of autophagy 
does not seem to be a key mechanism underlying the 
anti-atrophic activity of VD3. 
 
Collectively, our findings suggest that VD3 
supplementation in vivo (where it is physiologically 
converted in 25VD, 1,25VD, and 24-hydroxylated 
products) can result in a combination of effects due to 
the simultaneous action of different vitamin D 
metabolites, each of which with its own pro- or anti-
atrophic activity [10]. Moreover, although C2C12 
myotubes do not express Cyp2r1, this 25-hydroxylase is 
present in the whole muscle [42, 43], thus possibly 
transforming VD3 in 25VD. Although VD3 did not 
modulate the expression of the other hydroxylases 
involved in vitamin D metabolism (Figure 4), some of 
those may be modulated by other vitamin D metabolites 
[10, 20] and by systemic inflammation [44] in a tissue-
specific manner, further raveling the scenario and 
providing a putative explanation for the contrasting 
outcomes of VD3 supplementation in different 
conditions. In conclusion, our findings suggest the need 
to assess, before VD3 supplementation in vivo, the 
levels of as many as possible vitamin D metabolites as a 
readout of the activity of different hydroxylases, thus 
avoiding the increase of the pro-atrophic metabolites. 
Also, the design of VD3-derived not-hydroxylable 
molecules that maintain the anti-atrophic property of 
VD3 preventing the sequential hydroxylations that 
could result in pro-atrophic molecules might represent a 
prominent strategy to overcome the limitations of VD3 
supplementation in some pathological conditions. 
 




VD3 and 1,25VD were purchased from Cayman 
Chemicals (Ann Arbor, Michigan, USA) and dissolved 
in ethanol. IL-6 was from Peprotech (London, UK). 
Water-soluble dexamethasone was from Merck Life 
Science (Milan, Italy). The RXR antagonist PA 452 was 
from Tocris Bioscience (Bristol, UK), the anti-LC3 
antibody was from Proteintech (Rosemont, Illinois, 
USA), the anti-STAT3 and anti-phospho-STAT3Tyr705 
antibodies were from Cell Signaling Technology 
(Beverly, MA), and the anti-puromycin antibody was 
from Merck Life Science. The ELISA kit for 25VD 
quantification was from Enzo Life Sciences (Lausen, 
Switzerland). All other reagents, unless otherwise 
stated, were from Merck Life Science. 
 
Cell cultures and myotube analysis 
 
C2C12 myoblasts were grown at low density in  
DMEM (Gibco, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) supplemented with 10% fetal 
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bovine serum (FBS, Gibco, Thermo Fisher Scientific), 
100 U/mL penicillin, 100 μg/mL streptomycin, and 0.25 
μg/mL antimycotic in a humidified 5% CO2 incubator at 
37° C. To induce differentiation, cells were allowed to 
become confluent, and the medium was switched to 
differentiation medium (DM), consisting in DMEM 
supplemented with 2% horse serum (GE Healthcare Bio-
Sciences, Uppsala, Sweden), penicillin, streptomycin, 
and antimycotic as described above. Unless otherwise 
specified, myotubes were treated after at least 4 days of 
differentiation in serum-free medium. Control cells were 
treated with ethanol. Myotube diameters were measured 
with ImageJ software as previously described [45].  
 
HepG2 (human hepatoma) cells were cultured in 
DMEM supplemented with 10% FBS and penicillin, 
streptomycin, and antimycotic as above. Before 
treatments, cells were cultured overnight in serum-free 
medium.  
 
Differentiation index and fusion index 
 
Differentiation and fusion indexes were calculated as 
number of myosin heavy chain (MyHC)-positive cells 
above the total number of nuclei and average number of 
nuclei in myotubes with at least 3 nuclei above the total 
nuclei, respectively, as previously described [46]. 
 
Myofiber isolation and culture 
 
Single myofibers were isolated as previously described 
[47]. Briefly, EDL muscles from C57BL/6 mice were 
digested in 0.2% collagenase type-I in DMEM for 60–70 
minutes at 37° C. Muscles were mechanically 
dissociated, and single fibers liberated. After extensive 
washing, myofibers were cultured in low proliferation 
medium (LPM, DMEM supplemented with 10% HS and 
0.5% CEE) in suspension. Treatments were added in 
LPM immediately after fiber seeding, and 24 h later 
fibers were fixed in 4% PFA for 10 minutes. Myofiber 
microphotographs (10 per treatment, 10X magnification) 
were acquired with a bright field microscopy (Zeiss), and 




At the end of the indicated treatments, cells were 
washed in ice-cold PBS and solubilized with a lysis 
buffer containing 1% Triton X-100, 0.1% sodium 
deoxycholate, 0.1% sodium dodecyl sulfate, 1 mM 
EDTA, 1 mM EGTA, 50 mM NaF, 160 mM NaCl, 
20mM Tris-HCl, pH 7.4, and supplemented with 
protease inhibitor cocktail. Lysates were stirred at 4° C 
for 15 minutes and centrifuged at 15 000 g for 15 
minutes at 4° C. Protein concentration was determined 
by BCA protein assay kit (Thermo Fisher Scientific). 
Proteins (10-20 μg protein/lane) were separated by 10% 
or 15% SDS-PAGE and transferred to polyvinylidene 
difluoride filters (PVDF) (Hybond-P; GE Healthcare, 
Little Chalfont, Buckinghamshire, UK). Membranes 
were saturated with 4% bovine serum albumin (BSA), 
incubated with the primary antibodies (1:1000) 
overnight, washed with Tris buffered saline (TBS) 0.1% 
Tween, incubated with the appropriate secondary 
antibody (1:3000; Invitrogen, Thermo Fisher 
Scientific), visualized with Western Lightning 
Chemiluminescence Reagent Plus (PerkinElmer Life 
and Analytical Sciences, Waltham, Massachusetts, 
USA), acquired with ChemiDoc Touch (Bio-Rad, 
Hercules, California, USA), and analyzed with 
ImageLab (Bio-Rad). After anti-phospho-STAT3Tyr705, 
membranes were stripped with Restore Plus Western 
blot stripping buffer (Thermo Fisher Scientific) and 
reblotted with the corresponding total protein antibody. 
 
SUnSET protein synthesis assay 
 
Protein synthesis was evaluated by SUnSET assay [48]. 
Differentiated myotubes were treated with 100 nM VD3 
in serum-free medium for 24 h, and, 30 minutes before 
cell lysis, 500 ng/mL puromycin was added to the 
medium. After western blotting with an anti-puromycin 
antibody, membranes were stained with Ponceau S red 
to visualize total proteins. Both western blots and 
stained membranes were acquired with ChemiDoc 
Touch (Bio-Rad, Hercules, California, USA), and 
analyzed with ImageLab (Bio-Rad). 
 
AKT pathway phosphorylation array 
 
Cells were solubilized as for western blotting, and 
mouse AKT pathway phosphorylation arrays C1 
(RayBiotech, Inc, Norcross, Georgia, USA) were used 
according to manufacturer instructions.  
 
Intracellular quantification of 25VD 
 
C2C12 myotubes and HepG2 cells were treated for 24 h 
with 100 nM VD3. At the end of the treatment, cells were 
washed in ice-cold PBS and solubilized with a lysis buffer 
containing 1% Triton X-100, 0.5% sodium deoxycholate, 
1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 100 mM 
Tris-HCl, pH 7.4. Lysates were stirred at 4° C for 15 min 
and centrifuged at 15 000 g for 15 minutes at 4° C. The 
amount of 25VD produced by the cells was quantified 
using the 25(OH) Vitamin D ELISA Kit (Enzo Life 




For differentiation and fusion index quantification, 
myotubes were fixed in cold methanol:acetone 1:1 for 
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10 minutes, permeabilized with 0.2% triton for 5 
minutes and blocked with 4% BSA for 30 minutes. 
Primary antibody to detect MyHC (1:10; 
Developmental Studies Hybridoma Bank, Iowa City, 
IA) was incubated overnight at 4° C, and the secondary 
antibody (Alexa Fluor Dyes-conjugated 488 anti-rabbit 
1:400; Thermo Fisher Scientific) for 1 h at RT, followed 
by 5 minutes of DAPI. Images were acquired with an 
EVOS™ XL Core Imaging System (ThermoFisher 
Scientific) and quantification was performed with 
ImageJ.  
 
For LC3 detection, C2C12 myotubes were fixed in 4% 
paraformaldehyde for 10 minutes, washed with PBS, 
permeabilized with HEPES-TRITON X-100 0.5% for 5 
minutes, and washed two times with PBS-0.2% BSA. 
For blocking the unspecific binding sites, cells were 
incubated in 4% BSA for 1 h at RT. LC3-positive 
puncta were evaluated by incubation for 1 h with rabbit 
anti-LC3 (1:100), followed by the appropriate Alexa 
Fluor Dye-conjugated secondary antibody (488 anti-
rabbit 1:400; Thermo Fisher Scientific). Nuclei were 
counterstained with DAPI (1:100, Thermo Fisher 
Scientific). Images were acquired with a Leica dm 
5500b fluorescence microscope (Leica, Wetzlar, 
Germany) equipped with Leica Application Suite X 
software, using a 40X objective, and fluorescence 
signals, normalized to the area of myotubes, were 
quantified with ImageJ software. 
 
Proximity ligation assay (PLA) 
 
For the PLA (Duolink, Merck Life Science), the 
manufacturer instructions were slightly modified to 
allow the identification of myoblasts and myotubes. In 
brief, C2C12 cells were plated and differentiated on 
glass coverslips. At the end of the indicated treatments, 
myotubes were rinsed three times with PBS and fixed in 
4% PFA in PBS for 10 minutes. The cells were 
permeabilized in 0.2% Triton X-100 for 5 minutes and 
blocked with 4% BSA in PBS for 60 minutes at 37° C. 
After blocking, cells were incubated with antibodies 
against VDR (1:50, Santa Cruz Biotechnology, Santa 
Cruz, CA), RXR (1:50, Proteintech, Rosemont, Illinois, 
USA), and MyHC (1:10) in PBS overnight at 4° C, 
followed by incubation with the corresponding 
secondary antibodies conjugated with PLA probes for 
60 minutes at 37° C in the dark. Cells were washed 
three times in PBS. Duolink and DAPI signals were 
detected using the 40X objective on the Leica dm 5500b 
fluorescence microscope. 
 
RNA extraction and analysis 
 
Total RNA from myotubes was extracted by RNAzol 
(SigmaAldrich). The RNA was retro-transcribed with 
High-capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Thermo Fisher Scientific) and real-time PCR 
was performed with the StepOnePlus Real-time PCR 
System (Applied Biosystems, Thermo Fisher Scientific), 
using the following TaqMan probes (Thermo  
Fisher Scientific): Mm00499518_ m1 (Fbxo32,  
Atrogin-1/MAFbx), Mm00487244_m1 (Cyp24a1), 
Mm01165918_g1 (Cyp27b1), Mm00470430_m1 
(Cyp27a1), Mm00437297_m1 (Vdr), Mm00433130_m1 
(Pdia3), Mm01159413_m1 (Cyp2r1), Mm01197698_m1 
(Gusb). 
 
VDR and PDIA3 silencing 
 
A concentration of 10 nM of Vdr siRNA, Pdia3 siRNA 
(Integrated DNA Technologies), or siRNA negative 
control sequence (Integrated DNA Technologies) was 
transfected with Lipofectamine 3000 (Invitrogen, Thermo 
Fisher Scientific) in C2C12 at day 3 of differentiation. 
Myotubes underwent treatments with IL6 and VD3 24 h 
later. Transfection of myotubes with Block-iT (Invitrogen, 
Thermo Fisher Scientific) was used to assess transfection 




The investigators quantifying the experimental 
outcomes were maintained blinded to the treatments and 
the statistic evaluation of the experimental data was 
performed by another investigator not directly involved 
in data collection and parameters measurement.  
 
Unless otherwise specified, at least triplicate samples 
from three independent experiments were analyzed. 
Data are presented as the mean ± SEM. Outliers in the 
measurements were identified by mean of the 
interquartile range (IQR), as either below Q1 - 1.5 IQR 
or above Q3 + 1.5 IQR, and excluded from the analysis. 
The variation among groups was evaluated using 
ANOVA test followed by Tukey’s Multiple 
comparisons test unless otherwise stated. Statistical 
significance was assumed for P < 0.05. All statistical 




1,25D3-MARRS: Membrane-Associated, Rapid 
Response Steroid binding; 1,25VD: 1,25-dihydroxy 
vitamin D3, 1,25(OH)2D3, calcitriol; 1α-OHase: 1α-
hydroxylase; 24,25VD: 24,25-dihydroxy vitamin D3, 
24,25(OH)2D3; 25-OHases: 25-hydroxylases; 25VD: 
25-hydroxycholecalciferol, 25(OH)D3; Akt: Protein 
kinase B; ANOVA: Analysis of variance; BCA: 
Bicinchoninic acid; BSA: Bovine serum albumin; CEE: 
Chicken embryo extract; CLQ: Chloroquine; DAPI: 
4′,6-diamidino-2-phenylindole; DEXA: Dexamethasone; 
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DM: Differentiation medium; DMEM: Dulbecco’s 
Modified Eagle Medium; EDL: Extensor Digitorum 
longus; EDTA: Ethylenediaminetetraacetic acid; 
EGTA: Ethylene glycol-bis(2-aminoethylether)-
N,N,N′,N′-tetraacetic acid; ELISA: Enzyme-linked 
immunosorbent assay; FBS: Fetal bovine serum; GR: 
Glucocorticoid Receptor; GREs: Glucocorticoid-
Responsive Elements; HS: Horse serum; HEPES: 4-(2-
HydroxyEthyl)-1-PiperazineEthanesulfonic Acid; IF: 
Immunofluorescence; IL6: Interleukin 6; IQR: 
Interquartile range; JAK2: Janus kinase 2; LC3: Light 
Chain 3; LPM: Low proliferation medium; MAFbx: 
Muscle Atrophy F-box; mTOR: Mechanistic target of 
rapamycin; MyHC: Myosin heavy chain; PBS: 
Phosphate-buffered saline; PCR: Polymerase chain 
reaction; Pdia3: Protein disulfide-isomerase A3; PFA: 
Paraformaldehyde; PLA: Proximity ligation assay; 
PVDF: Polyvinylidene difluoride; RT: Room 
temperature; RXR: retinoid X receptor; Q1: First 
quartile; Q3: Third quartile; SD: Standard deviation; 
SDS: Sodium Dodecyl Sulfate; SDS-PAGE: Sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis; 
SEM: Standard error of the mean; SRC-1: Steroid 
Receptor Coactivator-1; STAT3: Signal transducer and 
activator of transcription 3; SUnSET: SUrface SEnsing 
of Translation; TBS: Tris-buffered saline; VD: Vitamin 
D; VD3: Cholecalciferol, Vitamin D3; VDR: Vitamin D 
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